Mannatech (MTEX) Competitors $9.51 +1.52 (+19.02%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$10.45 +0.94 (+9.88%) As of 06:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. GNTA, CLNN, LIMN, ABVC, MNOV, COEP, APLT, ANL, NRXP, and GANXShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Genenta Science (GNTA), Clene (CLNN), Liminatus Pharma (LIMN), ABVC BioPharma (ABVC), MediciNova (MNOV), Coeptis Therapeutics (COEP), Applied Therapeutics (APLT), Adlai Nortye (ANL), NRx Pharmaceuticals (NRXP), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Its Competitors Genenta Science Clene Liminatus Pharma ABVC BioPharma MediciNova Coeptis Therapeutics Applied Therapeutics Adlai Nortye NRx Pharmaceuticals Gain Therapeutics Genenta Science (NASDAQ:GNTA) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Do insiders & institutionals have more ownership in GNTA or MTEX? 15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, GNTA or MTEX? Genenta Science has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Which has higher earnings and valuation, GNTA or MTEX? Mannatech has higher revenue and earnings than Genenta Science. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$9.64MN/AN/AMannatech$117.87M0.15$2.49M-$2.04-4.66 Do analysts recommend GNTA or MTEX? Genenta Science presently has a consensus target price of $25.00, indicating a potential upside of 695.92%. Given Genenta Science's stronger consensus rating and higher probable upside, research analysts plainly believe Genenta Science is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GNTA or MTEX more profitable? Genenta Science has a net margin of 0.00% compared to Mannatech's net margin of -3.46%. Genenta Science's return on equity of 0.00% beat Mannatech's return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Mannatech -3.46%-48.60%-10.70% Does the media refer more to GNTA or MTEX? In the previous week, Mannatech had 2 more articles in the media than Genenta Science. MarketBeat recorded 2 mentions for Mannatech and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.89 beat Mannatech's score of 0.94 indicating that Genenta Science is being referred to more favorably in the media. Company Overall Sentiment Genenta Science Very Positive Mannatech Positive SummaryGenenta Science beats Mannatech on 8 of the 13 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.20M$2.53B$5.74B$10.30BDividend YieldN/A59.99%5.86%4.62%P/E Ratio-4.6623.2976.8526.52Price / Sales0.15486.45453.0387.93Price / Cash3.74169.8537.2260.63Price / Book2.085.2913.686.31Net Income$2.49M$32.95M$3.29B$271.37M7 Day Performance17.12%-1.29%-0.75%0.57%1 Month Performance11.49%3.50%3.84%6.20%1 Year Performance26.29%-3.48%82.85%28.33% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech0.9902 of 5 stars$9.51+19.0%N/A+25.8%$15.20M$117.87M-4.66250Short Interest ↓Gap UpHigh Trading VolumeGNTAGenenta Science2.7759 of 5 stars$3.56+3.5%$25.00+602.2%-4.8%$65.11MN/A0.007CLNNClene3.1718 of 5 stars$6.51-1.8%$33.00+406.9%+16.6%$64.89M$340K-1.73100LIMNLiminatus PharmaN/A$2.49+7.8%N/AN/A$64.77MN/A0.00N/APositive NewsABVCABVC BioPharma0.5618 of 5 stars$2.69-1.3%N/A+338.0%$63.68M$510K-15.9130MNOVMediciNova2.1756 of 5 stars$1.29+2.0%$7.00+444.7%-27.8%$63.03M$134.60K-5.1410COEPCoeptis Therapeutics0.6457 of 5 stars$13.06+0.8%N/A+250.0%$62.93MN/A-2.252Positive NewsAPLTApplied Therapeutics4.0383 of 5 stars$0.43-1.9%$6.10+1,312.0%-91.2%$62.64M$460K-0.9730News CoveragePositive NewsGap UpANLAdlai Nortye1.9635 of 5 stars$1.69-0.6%$9.00+432.5%-19.6%$62.36M$5M0.00127NRXPNRx Pharmaceuticals3.3462 of 5 stars$3.12+9.9%$34.50+1,005.8%+78.0%$62.18MN/A-1.402Positive NewsGANXGain Therapeutics2.7857 of 5 stars$1.73-1.4%$8.00+363.8%+5.7%$62.05M$50K-2.7420 Related Companies and Tools Related Companies GNTA Alternatives CLNN Alternatives LIMN Alternatives ABVC Alternatives MNOV Alternatives COEP Alternatives APLT Alternatives ANL Alternatives NRXP Alternatives GANX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTEX Stock Alerts